Goadsby, Peter J. et al "Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study (S17.001)." Neurology 92.15 Supplement (2019): S17.001. Web. 25 Jan. 2022.